Maia Biotechnology, Inc.

MAIA

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001878313

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $9.7M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, thin data, degenerate inputs not computable: short runway, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 23, 2026 217 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026
Last close	$1.15 2026-10-23; market equity $69.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 23, 2026

MAIA Biotechnology, Inc. (MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Ateganosine (THIO, 6-thio-dG or 6-thio-2 ?-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In July 2022, the first patient was administered with ateganosine in our Phase 2 human trial (THIO-101) in Australia. In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101, Phase 2 clinical trial evaluating ateganosine in patients with Non-Small Cell Lung Cancer (NSCLC).

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 11.4						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(35.8%)	(6.6%)	11.4	807	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 83.3					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(50.68)	(0.33)	89.2	752	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	1.66x	2.94x	77.3	834	2025-12-31
Growth and financing, sleeve percentile 73.5					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 3					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(6.9%)	2.1%	64.5	700	2025-12-31
Net share issuance, one year	105.1%	2.5%	82.5	636	2026-03-23

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 105.1%
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(14.9%)	7.7%	36
Distance from 52-week high	(61.0%)	(31.4%)	20
EBIT to enterprise value	(34.7%)	(1.5%)	19
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.30	0.28	51
Sales to price	0.00	0.30	0
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.37)	(0.14)	36

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$0
Operating cash flow, four quarters	-$22.6M
Months of runway	not finite
Days since last periodic filing	77 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	$481,989

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$22.4M	2025-12-31	2026-03-23	10-K	26-012088
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.8M	2025-12-31	2026-03-23	10-K	26-012088
3	assets	us-gaap:Assets	$9.7M	2025-12-31	2026-03-23	10-K	26-012088
4	assets	us-gaap:Assets	$10.2M	2024-12-31	2026-03-23	10-K	26-012088
5	current assets	us-gaap:AssetsCurrent	$9.7M	2025-12-31	2026-03-23	10-K	26-012088
6	current liabilities	us-gaap:LiabilitiesCurrent	$5.8M	2025-12-31	2026-03-23	10-K	26-012088
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$109.6M	2025-12-31	2026-03-23	10-K	26-012088
8	operating income	us-gaap:OperatingIncomeLoss	-$24.3M	2025-12-31	2026-03-23	10-K	26-012088
9	book equity	us-gaap:StockholdersEquity	$2.4M	2025-12-31	2026-03-23	10-K	26-012088
10	liabilities	us-gaap:Liabilities	$7.3M	2025-12-31	2026-03-23	10-K	26-012088
11	operating income	us-gaap:OperatingIncomeLoss	-$17.0M	2024-12-31	2026-03-23	10-K	26-012088
12	interest expense	us-gaap:InterestExpense	$57	2024-12-31	2025-03-21	10-K	25-043190
13	revenue	us-gaap:Revenues	$0	2024-12-31	2025-03-21	10-K	25-043190
14	revenue	us-gaap:Revenues	$0	2023-12-31	2024-03-21	10-K	24-034764
15	revenue	us-gaap:Revenues	$0	2022-12-31	2023-03-24	10-K	23-009766
16	assets	us-gaap:Assets	$7.6M	2023-12-31	2025-03-21	10-K	25-043190
17	assets	us-gaap:Assets	$12.0M	2022-12-31	2024-03-21	10-K	24-034764
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	60,671,491	2026-03-23	2026-03-23	10-K	26-012088
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	29,587,314	2025-03-21	2025-03-21	10-K	25-043190

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.